Diagnostic company Oxford Immunotec of Marlborough, which also holds offices in Oxford, United Kingdom, will provide T-cell testing to the UK Vaccines Taskforce, a group formed by the government to assess vaccine suitability for the country’s residents.
T-cells have played an increasingly important role in SARS-CoV-2 infection and immunity, according to Oxford Immunotec, which is why the UK Vaccines Taskforce is including T-Cell analysis in its COVID-19 vaccine trials.
The company’s T-SPOT technology platforms enables easy centralization of fresh blood samples from different study locations, and also standardizes measurement of T-cell responses, according to Oxford Immunotec.
Oxford Immunotec CEO Peter Wrighton-Smith said in a statement the company was excited to work with the taskforce and assist with vaccine development.
